Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
g-
r-
j-
P-
P-
H-
F-
z-
Who said differently? The sky is blue the grass is green ...
No idea what would you like to say ...
Best,
G
r-
r-
M-
r-
N-
m-
H-
I will later.
Best,
G
K-
Because The Eagle Doesn't Catch Flie ...
Best,
G
ps.: Did you ever argued the $200+ / share BO price with anybody ... top of laughing?
btw: I replied to YOUR post ... Why do you think I "have to" review ... seriously
N-
K-
a.) The Eagle Doesn't Catch Flie
b.) Do you think Vascepa (with cardio limitation on label till Dec 13, 2019) was not used / was not usable for cardiac benefit under 500 trigs ...? Acc. to my best, non-pettifogger knowledge prescribers could write, patient could use any drug for any indication ... independently from the label
Best,
G
r-
dmlcento (#327699; 327704) & Number sleven (#327702) &
Whalatane (#327705) & oneragman (#327712) & studythosestocks (#327716)
First of all:
K- (& studythosestocks #327693)
Seriously (not bickering): What is your expectation about - what will be the outcome / result of - Amarin vs Hikma / Net Health case? (Assuming Amarin will win every arguments).
Best,
G
t-
t-
g-
d- (& rafunrafun #326606)
First of all: sorry for my typo. Correctly:
d- (& rafunrafun #326598)
r-
I-
r-
d-
r-
d-
h-